CAMP4 Therapeutics Corp

camp4tx.com

What Do They Do?

Develops RNA-targeting drug candidates designed to increase gene expression for patients with genetic diseases, focusing on disorders of the brain and nervous system.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $80.4M in FY2025.

Operating income, FY2025

−1502% of revenue

▼ −1% (Loss) vs FY2024 (−$53.1M, −8142%)

Net income, FY2025

−2298% of revenue

▲ +55% (Loss) vs FY2024 (−$51.8M, −7943%)

Free cash flow, FY2025

−854% of revenue

▼ −35% (Loss) vs FY2024 (−$46M, −7056%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +19%; vs $1.5M in Q2 FY2025
Net income: ▲ +166% (Loss); vs −$12.6M in Q2 FY2025

Aug 4, 2026 Completed the second private-placement closing Issued common shares and pre-funded warrants for approximately $50.1 million in gross proceeds.
Jul 27, 2026 Received clearance to initiate a Phase 1/2 clinical trial Australia’s therapeutic regulator and local ethics committee cleared the trial of its SYNGAP1 candidate.

Who Do They Compete With?

Competes with Stoke Therapeutics, Acadia Pharmaceuticals, Praxis Precision Medicines, GondolaBio, Tevard Biosciences, Regel Therapeutics, Quiver Bioscience, Amgen, Ultragenyx Pharmaceutical, Arcturus Therapeutics Holdings, iECURE, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals

Comments